ProCE Banner Activity

KEYNOTE-826: Final OS Analysis of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Persistent, Recurrent, or Metastatic Cervical Cancer

Conference Coverage
Slideset

Pembrolizumab added to platinum-based chemotherapy with or without bevacizumab reduced the risk of death by approximately 40% compared with placebo for women with persistent, recurrent, or metastatic cervical cancer in this final planned analysis of OS from KEYNOTE-826.

Released: June 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, and Merck Sharp & Dohme Corp.

AstraZeneca

GSK

Merck Sharp & Dohme Corp.